News

Laboratoires Réunis group is a further client for bio.logis Genetic Information Management GmbH’s “Genetic Information Management Suite (GIMS)”, specially developed for genetic diagnostics. Usage will initially focus on establishing the creation of highly complex diagnostic reports with a maximum degree of efficiency and automation.

The “pharma.sensor” developed by bio.logis Genetic Information Management GmbH (bio.logis GIM) is a new mobile app for pharmacogenomics. The app shows whether certain DNA variants have to be considered for the safe efficacy of a drug. With this knowledge, the app user can identify if genotyping is useful prior of starting a drug therapy. The drug check is performed by simply entering a drug name or scanning the barcode on the packaging. The app is available in German and English via the Apple app store and is free of charge.

bio.logis Genetic Information Management GmbH was present at the European Human Genetics Conference from May 27 to 30, 2017.

The "Genetic Information Management Suite", or GIMS in short, supports laboratories in efficiently translating laboratory findings into clinically leverageable and easily understood information for physicians and patients. At the heart of the software suite is the "Diagnostic Report Module", or DRM, enabling up to 95% of cost and time savings when creating diagnostic reports. With the introduction of the "Report Layout Engine" (RLE), bio.logis is expanding GIMS by another key building block to respond yet more flexibly to the requests and needs of diagnostic laboratories.

This EU-funded project is part of the Horizon 2020 program “Ubiquitous Pharmacogenomics“ (U-PGx) and aimed at driving the implementation of pharmacogenetics in diagnostic and clinical practice. The objective is to treat patients with medication and doses that are ideally suited to their personal genetic make-up. As part of this project, bio.logis Genetic Information Management GmbH, based in Frankfurt, will make its GIMS Genetic Information Management Suite available, which was specifically developed for genetic diagnostics. GIMS has now been implemented in the first three of a total of seven European university hospitals, enabling maximized efficiency in creating customized reports with easily understood pharmacogenetic recommendations for physicians and patients.

Last weekend bio.logis contributed to a successful Drupal Camp 2017 in Frankfurt with 3 sessions, 1 informal discussion group (“Birds of a feather” session, BoF) and a Gold Sponsorship.

bio.logis Genetic Information Management GmbH has achieved the next decisive level for establishing its Genetic Information Management Suite (GIMS) as a quality product for genetic diagnostics: The software suite’s currently most important component—the Diagnostic Report Module (DRM)—has been certified by the Federal Association for Internet Medicine (BiM) as an “Internet medicine quality product” and has also received the CE mark as a Medical Device Class I (according to EEC 93/42, EC 2007/47).

Pharmacogenomics deals with the questions of whether an individual's genetic make-up affects the efficacy of drugs and/or how to leverage genetic information to optimize drug therapies. The buzz word is: Personalized medicine. The EU is now making a total of €15m available for driving the practical implementation of genetic knowledge to improve therapeutic decision-making. This supports the European U-PGx (Ubiquitous Pharmacogenomics) consortium. bio.logis Genetic Information Management GmbH, based in Frankfurt am Main, Germany, is a member of this consortium and has been concentrating on the issue for years, with a specific focus on developing genetic information management systems. bio.logis will receive €2.4m from these funds to implement its Genetic Information Management Suite (GIMS) along with technologies for genotyping in selected hospitals across Europe (the Netherlands, UK, Austria, Greece, Italy, Spain, Slovenia) for application in day-to-day clinical operations.